Deloitte Corporate Finance LLC Advises Sina Drug Corporation in its Investment from PharMerica Corporation
CHARLOTTE, N.C., Feb. 4, 2014 — Deloitte Corporate Finance LLC (“DCF”) acted as the exclusive financial advisor to Sina Drug Corporation (DBA “Onco360”) in its investment from PharMerica Corporation (“PharMerica”). As the largest independent provider of oncology pharmacy services in the United States, Onco360 will serve as a key strategic addition to PharMerica’s pharmacy and care management platform.
“Onco360 has built a reputation as a specialty oncology pharmacy and clinical support services organization, and we were pleased to have advised them in this transaction,” said Dave Vorhoff, managing director, DCF, and co-head of DCF’s life sciences and healthcare group.
Onco360 is the largest independent provider of Oncology Pharmacy Services in the country. Onco360 serves the specialized needs of oncologists, patients, hospitals, cancer centers, manufacturers, and health plans. The company’s clinical and dispensing model was developed specifically to meet the unique needs of oncology-treating physicians and their patients. Onco360 is focused on bringing together stakeholders of the cancer treatment process, and as part of this effort the company is advancing the continuum of oncology pharmaceutical care through patient advocacy, dispensing excellence, and clinical expertise. Onco360 dispenses through its network JCAHO-accredited OncoMed Pharmacies.
PharMerica Corporation is a leading institutional pharmacy, specialty infusion and hospital pharmacy management services company servicing healthcare facilities in the United States. PharMerica operates pharmacies in 45 states. PharMerica’s customers are institutional healthcare providers, such as nursing centers, assisted living facilities, hospitals and other long-term care providers. In addition, the Company provides specialty infusion pharmaceuticals to patients in a home setting. The company also provides pharmacy management services to long-term care hospitals.
Deloitte Corporate Finance LLC, a FINRA-registered broker-dealer, is an indirect wholly-owned subsidiary of Deloitte Financial Advisory Services LLP and affiliate of Deloitte Transactions and Business Analytics LLP. Deloitte Corporate Finance LLC provides deal execution and lead financial advisory services to large corporate, middle market, and private equity firms. Deloitte Corporate Finance has access to the resources of the Corporate Finance Advisory practices of the member firms (and their affiliates) within the Deloitte Touche Tohmatsu Limited network of member firms. Together with Deloitte Corporate Finance LLC, these practices include in excess of 1,600 professionals, working collaboratively in 150 international locations. Investment banking products and services within the United States are offered exclusively through Deloitte Corporate Finance LLC. For more information, visit www.investmentbanking.deloitte.com.
As used in this document, “Deloitte” means Deloitte LLP and its subsidiaries. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries. Certain services may not be available to attest clients under the rules and regulations of public accounting.
Prior engagement performance is no guarantee of future performance and may not be representative of the experience of other clients. This communication is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security.